论文部分内容阅读
目的观察125I放射性粒子对肝门部胆管癌的临床治疗效果。方法78例肝门部胆管癌患者随机分成3组,A组经皮经肝胆管引流术(PTCD)27例、B组(125I粒子)39例及C组(PTCD+125I粒子)12例,通过观察术前术后总胆红素的改变、肿瘤大小的变化及患者的生存率,分析125I放射性粒子永久性植入治疗胆管癌的疗效。结果术后半个月,A,B,C 3组总胆红素下降率分别为81.5%(22/27),66.7%(26/39),83.3%(10/12),A,B两组及B,C两组差异均有显著性(P<0.05);术后1年3组(CR+PR)分别为29.6%(8/27),74.4%(29/39),75.0%(9/12),A,B两组及A,C两组差异均有显著性(P<0.05);术后6个月和12个月生存率,B组为89.7%,82.1%,C组为91.7%,83.3%,明显高于A组的59.3%,33.3%(P<0.05)。结论对肝门部胆管癌,125I放射性粒子有治疗作用,PTCD术为姑息性治疗,125I放射性粒子联合PTCD术可取得更佳效果。
Objective To observe the clinical effect of 125I radioactive particles on hilar cholangiocarcinoma. Methods Seventy-eight patients with hilar cholangiocarcinoma were randomly divided into three groups. Group A received 27 cases of percutaneous transhepatic biliary drainage (PTCD), 39 cases of group B (125I particles) and 12 cases of group C (PTCD + 125I particles) The changes of total bilirubin, tumor size and survival rate were observed before and after operation. The effect of permanent 125I radioactive seed implantation in the treatment of cholangiocarcinoma was analyzed. Results The decrease rates of total bilirubin in group A, B and C were 81.5% (22/27), 66.7% (26/39) and 83.3% (10/12) The CR + PR in 1 year after operation were 29.6% (8/27), 74.4% (29/39) and 75.0%, respectively (P <0.05) (P <0.05). The survival rates at 6 months and 12 months after operation were 89.7% and 82.1% in group B, and those in group C 91.7% and 83.3% respectively, which was significantly higher than 59.3% and 33.3% in group A (P <0.05). Conclusions For the hilar cholangiocarcinoma, 125I radioactive particles have a therapeutic effect. PTCD is a palliative treatment. 125I radioactive particles combined with PTCD can achieve better results.